Altimmune to Participate at Two Upcoming Investor Conferences
17 Octobre 2023 - 1:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will participate and be available for 1x1 meetings at the
following investor conferences:
- H.C. Wainwright 7th
Annual NASH Investor Conference (Virtual
Conference)Tuesday, October 24, 2023Presentation at 10:00
am Eastern Time
- H. C. Wainwright 4th
Annual Hepatitis B Virus (HBV) Virtual
ConferenceWednesday, October 25, 2023Fireside chat at 3:00
pm Eastern Time
The sessions will be webcast and can be accessed by visiting the
Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
therapeutics for the treatment of obesity and liver diseases. The
Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon
dual receptor agonist that is being developed for the treatment of
obesity and NASH. In addition, Altimmune is developing HepTcell™,
an immunotherapeutic designed to achieve a functional cure for
chronic hepatitis B. For more information, please visit
www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Altimmune Investor Contact:Richard
EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Media Contact:Danielle CanteyEvoke CanalePhone:
619-826-4657danielle.cantey@evokegroup.com
Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024